Decoding Zmiz1: a key transcription coactivator in development and disease.
- 1Department of Cell and Molecular Biology, Tulane University, New Orleans, LA, United States.
- 2Tulane Brain Institute, Tulane University, New Orleans, LA, United States.
Abstract
ZMIZ1, a zinc finger MIZ-type transcriptional co-activator in the PIAS family, is emerging as a central regulator at the interface of development and disease. Through interactions with key signaling effectors, including NOTCH1, SMAD3/4, p53, estrogen receptor, and androgen receptor, ZMIZ1 shapes transcriptional programs that govern embryogenesis, vascular and lymphatic development, and cerebral cortex development. Disruption of these programs is increasingly linked to human pathology: pathogenic ZMIZ1 variants cause a syndromic neurodevelopmental disorder with autism spectrum disorder and intellectual disability, and are associated with Hirschsprung disease, depression, and Lewy body disease. Beyond the nervous system, genetic and functional studies implicate ZMIZ1 in T-cell development and leukemia, multiple autoimmune diseases, type-2 diabetes, and a broad spectrum of cancers, including cutaneous squamous cell carcinoma, prostate, breast, colorectal cancer, osteosarcoma, and glioblastoma. Despite this expanding disease spectrum, the cell type-specific and context-dependent mechanisms by which ZMIZ1 integrates activation state from different signaling pathways, chromatin regulation, and transcription activation remain poorly understood. In this review, we synthesize current knowledge of ZMIZ1 and molecular regulatory networks across developmental, neurological, immune, metabolic, and oncologic contexts. We highlight convergent themes in ZMIZ1 biology, outstanding mechanistic questions, and emerging evidence supporting ZMIZ1 and its downstream pathways as potential diagnostic, prognostic, and therapeutic targets in human disease. By integrating genetic, molecular, and systems-level evidence across diverse organs and diseases, this review proposes a working model of ZMIZ1 as a partner-directed, dosage-sensitive transcriptional rheostat, identifies experiments required to test it, and appraises the current, largely preclinical, evidence for its clinical potential.
Related
- Uncertainty-Aware structured decoding for Chinese Braille document transcription
- Editorial: Decoding the gut-brain axis: implications for neurodegenerative disease therapies
- Dose-dependent sensitivity of human three-dimensional chromatin to a heart disease–linked transcription factor
- Decoding sequence determinants of gene expression in diverse cellular and disease states
- The transcription factor PRO44 and the histone chaperone ASF1 regulate distinct aspects of multicellular development in the filamentous fungus Sordaria macrospora.
BibTeX
@article{k2026decoding,
title = {{Decoding Zmiz1: a key transcription coactivator in development and disease.}},
author = {Rajan K C and Anoushka Shenoy and Most Ayesha Siddika and Nehal R Patel and Stryder M Meadows and Maria J Galazo},
journal = {Frontiers in cell and developmental biology},
year = {2026},
month = oct,
doi = {10.3389/fcell.2026.1933470},
url = {https://europepmc.org/article/MED/42923466},
note = {CC BY},
}
RIS
TY - JOUR
TI - Decoding Zmiz1: a key transcription coactivator in development and disease.
AU - Rajan K C
AU - Anoushka Shenoy
AU - Most Ayesha Siddika
AU - Nehal R Patel
AU - Stryder M Meadows
AU - Maria J Galazo
PY - 2026
DA - 2026/10/08
JO - Frontiers in cell and developmental biology
DO - 10.3389/fcell.2026.1933470
UR - https://europepmc.org/article/MED/42923466
AB - ZMIZ1, a zinc finger MIZ-type transcriptional co-activator in the PIAS family, is emerging as a central regulator at the interface of development and disease. Through interactions with key signaling effectors, including NOTCH1, SMAD3/4, p53, estrogen receptor, and androgen receptor, ZMIZ1 shapes transcriptional programs that govern embryogenesis, vascular and lymphatic development, and cerebral cortex development. Disruption of these programs is increasingly linked to human pathology: pathogenic ZMIZ1 variants cause a syndromic neurodevelopmental disorder with autism spectrum disorder and intellectual disability, and are associated with Hirschsprung disease, depression, and Lewy body disease. Beyond the nervous system, genetic and functional studies implicate ZMIZ1 in T-cell development and leukemia, multiple autoimmune diseases, type-2 diabetes, and a broad spectrum of cancers, including cutaneous squamous cell carcinoma, prostate, breast, colorectal cancer, osteosarcoma, and glioblastoma. Despite this expanding disease spectrum, the cell type-specific and context-dependent mechanisms by which ZMIZ1 integrates activation state from different signaling pathways, chromatin regulation, and transcription activation remain poorly understood. In this review, we synthesize current knowledge of ZMIZ1 and molecular regulatory networks across developmental, neurological, immune, metabolic, and oncologic contexts. We highlight convergent themes in ZMIZ1 biology, outstanding mechanistic questions, and emerging evidence supporting ZMIZ1 and its downstream pathways as potential diagnostic, prognostic, and therapeutic targets in human disease. By integrating genetic, molecular, and systems-level evidence across diverse organs and diseases, this review proposes a working model of ZMIZ1 as a partner-directed, dosage-sensitive transcriptional rheostat, identifies experiments required to test it, and appraises the current, largely preclinical, evidence for its clinical potential.
SN - 2296-634X
ER -